About this trial
This pilot randomized controlled trial aims to evaluate the efficacy and feasibility of a virtual reality (VR)-guided mindfulness intervention for caregivers of patients with end-stage kidney disease (ESKD). Thirty ESKD caregivers will be randomly assigned to either a 6-week VR-guided mindfulness intervention or a sham VR control group. The study will assess changes in caregiver burden, stress, anxiety, depression, quality of life, and mindfulness using validated questionnaires. Feasibility outcomes, including recruitment, retention, adherence, and participant experiences, will also be evaluated. The findings will inform the design of a future larger-scale trial and may lead to the development of an accessible, technology-based support option for ESKD caregivers.
Eligibility criteria
Qualifiers
Age 21 years or older
Primary caregiver of a patient with end-stage kidney disease (ESKD) (stage 4 & 5 with - estimated glomerular filtration rate < 30 mL/min/1.73 m²)
Proficient in English
Disqualifiers
Known visual or hearing impairments
History of motion sickness
Active psychosis or suicidal ideation
Current regular mindfulness practice
Trial design
Treatments tested in this trial
- VR-guided mindfulness
- Sham VR